Kras

Overview

KRAS is a gene in the RAS family that encodes a small GTPase involved in transmitting signals from cell-surface receptors to intracellular pathways controlling proliferation, survival, and differentiation. In normal physiology, KRAS functions as a molecular switch, cycling between active and inactive states. When altered by mutation, it can become constitutively active and drive oncogenic signaling, making it one of the most important cancer-associated genes in human oncology.

Clinically, KRAS mutations are common across several solid tumors, including pancreatic ductal adenocarcinoma, non-small cell lung cancer, colorectal cancer, and biliary tract cancer. Recent research has emphasized both the therapeutic challenge of directly targeting KRAS and the broader biological consequences of KRAS-driven disease, including effects on the tumor microenvironment, immune evasion, and response to cancer immunotherapy, checkpoint inhibitor treatment, and tyrosine-kinase inhibitor-based strategies.

Focus of Latest Publications

Recent publications continue to position KRAS as a central therapeutic target across several KRAS-driven malignancies, with most studies focusing on pathway inhibition rather than KRAS itself as a direct biomarker. In appendiceal adenocarcinoma, KRAS inhibition was reported as an effective therapeutic approach, reflecting the high prevalence of KRAS mutations in this rare cancer and the need for better treatment options. In pancreatic cancer, however, combined inhibition of EGFR and RAF with erlotinib plus the pan-RAF inhibitor LXH-254 robustly suppressed MAPK signaling and reduced proliferation in vitro, but did not improve survival or tumor burden in orthotopic and genetically engineered mouse models, underscoring the difficulty of translating KRAS-pathway targeting into in vivo benefit.

Several studies examined strategies to suppress KRAS signaling indirectly through upstream regulators or combination regimens. A new SOS1 inhibitor, SL43, showed strong binding to SOS1, disrupted the SOS1-KRASG12C interaction, inhibited SOS1-mediated nucleotide exchange across multiple KRAS mutants, and produced selective antitumor activity in KRAS-mutant colorectal cancer models with oral bioavailability and no observable systemic toxicity in the xenograft study. Another report evaluated adding BKM120, a PI3K inhibitor, to a BI-3406 plus trametinib combination, specifically testing whether broader pathway blockade could improve the balance between efficacy and side effects in KRAS-targeted therapy. In parallel, a tumor-selective EGFR/B7-H3 bispecific antibody, IBI334, was shown to suppress downstream EGFR signaling and synergize with KRAS inhibitors in preclinical models, suggesting a potential combination strategy for KRAS-driven tumors.

Other publications highlighted mechanisms of resistance and clinical context relevant to KRAS-targeted treatment. In lung adenocarcinoma, HNF4α was described as promoting gastric identity in invasive mucinous adenocarcinoma and also increasing resistance to KRAS inhibition through enhanced NRF2 activity, pointing to cellular plasticity as a therapeutic vulnerability. In driver gene-positive non-small cell lung cancer, PD-L1 expression was associated with outcomes after targeted therapy, and among patients with KRAS mutations, first-line immunotherapy was associated with better survival, although high PD-L1 expression itself did not predict clear clinical benefit. Finally, in metastatic colorectal neuroendocrine carcinoma, KRAS mutations were less frequent than in colorectal adenocarcinoma and were associated with shorter overall survival only in rectal NEC, emphasizing that KRAS alterations may have different prognostic implications depending on tumor type and clinical setting.